Experience with rituximab in Purtscher retinopathy in a patient with systemic lupus erythematosus (a clinical case)

We present a clinical case of successful use of rituximab (RTM) as part of complex therapy in an Asian female patient with highly active systemic lupus erythematosus (SLE), lupus nephritis, and Purtscher retinopathy (PR) refractory to immunosuppressive therapy. This observation demonstrates not only a reduction in clinical and immunological disease activity parameters and proteinuria, indicating a partial renal response, but also a significant improvement in retinal perfusion according to optical coherence tomography angiography 5 months after RTM infusion, which made it possible to reduce the daily prednisolone dose. This case confirms the efficacy of RTM in refractory SLE-associated PR.

1. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011 Dec 1;365(22):2110-21. doi: 10.1056/NEJMra1100359.

2. Basiony AI, Elgouhary SM, Mohamed HE, et al. Assessment of retinal microvascular changes in patients with systemic lupus erythematosus using optical coherence tomography angiography. Int J Retina Vitreous. 2025 May 8;11(1):55. doi: 10.1186/s40942-025-00677-2.

3. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the LUNAR study. Arthritis Rheum. 2012 Apr;64(4): 1215-26. doi: 10.1002/art.34359.

4. Marmor MF, Kellner U, Lai TY, et al. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology. 2016 Jun; 123(6):1386-94. doi: 10.1016/j.ophtha.2016.01.058.

5. Wu C, Dai R, Dong F, Wang Q. Purtscherlike retinopathy in systemic lupus erythematosus. Am J Ophthalmol. 2014 Dec;158(6): 1335-1341.e1. doi: 10.1016/j.ajo.2014.09.001.

6. Agrawal A, McKibbin M. Purtscher's and Purtscher-like retinopathies: a review. Surv Ophthalmol. 2006 Mar-Apr;51(2):129-36. doi: 10.1016/j.survophthal.2005.12.003.

7. Abu Serhan H, Abuawwad MT, Taha MJJ, et al. Purtscher's and Purtscher-like retinopathy etiology, features, management, and outcomes: A summative systematic review of 168 cases. PLoS One. 2024 Jul 17;19(7):e0306935. doi: 10.1371/journal.pone.0306935.

8. Kao JH, Lai TT, Lu CH, et al. Characteristics and Potential Risk Factors of Hydroxychloroquine Retinopathy in Patients with Systemic Lupus Erythematosus: Focusing on Asian Population. J Ocul Pharmacol Ther. 2022 Dec;38(10):728-733. doi: 10.1089/jop.2022.0060.

9. Li M, Jin Y, He J. Purtscher-like retinopathy associated with systemic lupus erythematosus treated with rituximab plus low-dose interleukin-2: A case report. Int J Rheum Dis. 2023 Jul;26(7):1373-1376. doi: 10.1111/1756-185X.14623.

10. https://eyepress.ru/article/sluchay-manifestatsii-sistemnoy-krasnoy-volchanki-v-videokklyuziruyushchego-ret

11. Jakes RW, Bae SC, Louthrenoo W, et al. Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region. Arthritis Care Res (Hoboken). 2012 Feb;64(2):159-68. doi: 10.1002/acr.20683.

12. Yap EY, Au Eong KG, Poh WK, et al. Ophthalmic manifestations in Asian patients with systemic lupus erythematosus. Singapore Med J. 1998 Dec;39(12):557-9.

13. Popkova TV, Panafidina TA, Lila AM. Methodological guidelines (draft). Systemic lupus erythematosus: diagnosis, treatment, monitoring. Terapiya. 2025;(1):8-15. (In Russ.).

14. Solovyev SK, Mesnyankina AA, Nikishina NYu, et al. Treatment of patients with systemic lupus erythematosus without glucocorticoids – myth or reality? Modern Rheumatology Journal. 2022;16(1):81-88. (In Russ.). doi: 10.14412/1996-7012-2022-1-81-88.

15. Mazurov VI, Belyaeva IB, Gaydukova IZ. Clinical rheumatology: a guide for physicians. 3rd ed. Saint-Petersburg: Foliant; 2021. 696 p.

16. Magesan K, Nangia P, Manoharan A, et al. Systemic lupus erythematosus (SLE) associated uveitis in India – A case series. Indian J Ophthalmol. 2024 May 1;72(5):677-680. doi: 10.4103/IJO.IJO_1579_23.

17. Fanouriakis A, Kostopoulou M, Anders HJ, et al. EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis. 2026 Jan;85(1):75-90. doi: 10.1016/j.ard.2025.09.007.

18. Chen Y, Lei X, Xu J, et al. Belimumab versus telitacicept in sequential treatment after rituximab for refractory lupus nephritis: a real-world multicentre study. Lupus Sci Med. 2025 Jan 6;12(1):e001296. doi: 10.1136/lupus-2024-001296.

19. Wang W, He S, Zhang W, et al. BCMACD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial. Ann Rheum Dis. 2024 Sep 30;83(10): 1304-1314. doi: 10.1136/ard-2024-225785.